<DOC>
	<DOCNO>NCT00572325</DOCNO>
	<brief_summary>Our group show model study increase radiation dose pre-specified normal tissue dose constrains could lead increase TCP NTCP patient non-concurrent chemo-radiation . In subsequent phase I trial , patient receive non-concurrent chemo-radiation show safety approach . Here , want investigate efficacy prospective study patient stage III NSCLC , select radical concurrent radiotherapy</brief_summary>
	<brief_title>Concurrent Chemo-radiation Form NSCLC Individualized MLD</brief_title>
	<detailed_description>Eligible patient ( see ) receive radiotherapy primary tumor initially involve mediastinal lymph node follow MLD ( Mean Lung Dose ) : - MLD=19 Gy Fev1 DLCO &gt; 50 % predict value - MLD=15 Gy Fev1 and/or DLCO 40-49 % predict value - MLD=10 Gy Fev1 and/or DLCO &lt; 40 % predict value Other dose-constrains : spinal cord max : 54 Gy , brachial plexus ( Dmax ) :66 Gy Minimum tumor dose:54 Gy . Maximal tumor dose:69 Gy Radiotherapy deliver follow : 1 . First 3 week : 30 fraction : twice-daily fraction 1.5 Gy , 8 10 h interfraction-interval , 5 day per week Total dose ; 45Gy/30 fraction 2 . Thereafter : once-daily fraction 2.0 Gy , 5 day per week target dose reach . The radiation dose specify accord ICRU 50 . Lung density correction apply , well standard QA procedure . Technical requirement standard practice MAASTRO clinic . Chemotherapy schedule allow : 1 . 1-2 cycle induction chemotherapy ; type register . 2. concurrent part : ( day1= first day radiotherapy ) 1. cisplatin - vinorelbine - Cisplatin 50 mg/m2 day 2 day 9 - Vinorelbine 20 mg/m2 day 2 day 9 - Cisplatin 40mg/m2 day 23 - Vinorelbine 15mg/m2 day 23 day 30 2. cisplatin - docetaxel - Cisplatin 50 mg/m2 day 2,9 29 - Docetaxel 20 mg/m2 day 2 , 9 , 16 , 23 29 3. cisplatin - etoposide - Cisplatin 60 mg/m2 day 1 - Docetaxel 120 mg/m2 day 1-3 Q 3 week , 3 cycle When calculate creatinin clearance le 60 ml/min , cisplatin may substitute carboplatin</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histological cytological proven NSCLC UICC stage IIII Performance status 02 FeV 1 DLCO least 30 % agepredicted value Not NSCLC mixed NSCLC histology ( e.g . small cell carcinoma ) UICC stage IV Performance status 3 FeV 1 DLCO &lt; 30 % agepredicted value</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>radiotherapy</keyword>
	<keyword>NSCLC</keyword>
	<keyword>stage III non-small cell lung cancer</keyword>
</DOC>